The Buy rating and price target of $32 announced by Roth MKM analyst Dylan Dupuis for Viking Therapeutics (NASDAQ:VKTX) is likely to have a positive short-term impact on the stock price. This is because the Buy rating indicates the analyst's confidence in the company's growth potential, and the price target suggests a significant upside from the current stock price. Investors may consider this as a positive signal and increase their demand for the stock, driving the price up in the short term.